Page 1228 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

76. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis- 89. Passaro DJ, Werner SB, Mcbee J, et al. Wound botulism associ-
dermatomyositis associated interstitial lung disease. Am J Respir ated with black tar heroin among injecting drug users. JAMA.
Crit Care Med. 2001;164:1182. 1998;279:859.
77. Conners GR, Christopher-Stine L, Oddis CV, et al. Interstitial 90. Gottlieb SL, Kretsinger K, Tarkhashvili N, et al. Long-term
lung disease associated with idiopathic inflammatory myopa- outcomes of 217 botulism cases in the Republic of Georgia. Clin
thies. What progress has been made in the past 35 years? Chest. Infect Dis. 2007;45:174.
2010;138(6):1464-1474. 91. Dworkin MS, Shoemaker PC, Anderson DE. Tick paralysis: 33
78. Schnabel A, Reuter M, Biederer J, et al. Interstitial lung dis- human cases in Washington State, 1946–1996. Clin Infect Dis.
ease in polymyositis and dermatomyositis: clinical course and 1999;29:1435.
response to treatment. Semin Arthritis Rheum. 2003;32:273. 92. Diaz JH. A 60-year meta-analysis of tick paralysis in the United
https://kat.cr/user/tahir99/
79. Arakawa H, Yamada H, Kurihara Y, et al. Nonspecific interstitial States: a predictable, preventable, and often misdiagnosed
pneumonia associated with polymyositis and dermatomyositis. poisoning. J Med Toxicol. 2010;6:15.
Chest. 2003;123:1096. 93. Felz NW, Smith CD, Swift TR. A six-year old girl with tick
80. Joffe MM, Love LA, Leff RL, et al. Drug therapy of idiopathic paralysis. N Eng J Med. 2000;342:90.
inflammatory myopathies: predictors of response to predni- 94. Vedanarayanan V, Sorey WH, Subramony SH. Tick paralysis.
sone, azathioprine and methotrexate and a comparison of their Semin Neurol. 2004;24:181.
efficacy. Am J Med. 1993;94:379.
95. Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle
81. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term Nerve. 2003;27:142.
follow-up of intravenous immunoglobulin infusions in chronic
refractory polymyositis: an open study with thirty-five adult 96. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The
patients. Arthritis Rheum. 2002;46:467. effects of alcoholism on skeletal and cardiac muscle. N Eng J
Med. 1989;409:320.
82. Marie I, Hachulla E, Levesque H, et al. Intravenous immunoglob-
ulins as treatment of life threatening esophageal involvement in 97. Roth D, Alarcon FJ, Fernandez JA, et al. Acute rhabdomyolysis
polymyositis and dermatomyositis. J Rheumatol. 1999;26:2706. associated with cocaine intoxication. N Eng Med. 1988;319:673.
98. Lee P, Tai DY. Clinical features of patients with acute organic
83. Ytterberg SR. Treatment of refractory polymyositis and derma-
tomyositis. Curr Rhematol Rep. 2006;8(3):167. phosphate poisoning requiring intensive care. Intensive Care
Med. 2001;27:694.
84. Mahler EAM, Blom M, Voermans NC, et al. Rituximab treat-
ment in patients with refractory inflammatory myopathies. 99. Clay AS, Behnia M, Brown KK, et al. Mitochondrial disease.
Rheumatology. 2011;50:2206. A pulmonary and critical-care medicine perspective. Chest.
2001;120:634.
85. Fafalak RG, Peterson MGE, Kagen LJ. Strength in polymyositis
and dermatomyositis: best outcome in patients treated early. 100. Koopman WJH, WIllems PHGM, Smeitink JAM. Monogenic
J Rheumatol. 1994;21:643. mitochrondrial disorders. N Engl J Med. 2012;366:1132.
101. DiMauro S, Schon EA. Mitochondrial respiratory-chain
86. Arnon SS, Schechter R, Inglesby TV, et al. Botulism toxin as
a biologic weapon: medical and public health management. diseases. N Engl J Med. 2003;348:2656.
JAMA. 2001;285:1059. 102. Flaherty KR, Wald J, Weisman IM, et al. Unexplained exertional
limitation. Characterization of patients with a mitochondrial
87. Horowitz BZ. Botulinum toxin. Crit Care Clinics. 2005;21:825.
myopathy. Am J Respir Crit Care Med. 2001;164:425.
88. Vasa M, Baudendistel TE, Ohikhuare CE, et al. The eyes have it.
N Eng J Med. 2012;367(10):938. 103. McFarland R, Taylor RW, Turnbull DM. The neurology of
mitochondrial DNA disease. Lancet Neurol. 2002;1:343.

Section06-O-ref.indd 3 12/10/2014 6:03:41 PM